PTAB challenges

Proceedings overview

There is currently one active AIA trial proceeding on US Patent 11675791, an Inter Partes Review (IPR) filed by Teladoc Health, Inc., which is currently in the pending status.

IPR2026-00390 — Teladoc Health, Inc. v. Data Health Partners Inc

• Type: Inter Partes Review
• Filed: 2026-06-05
• Status: Pending (filed on 2026-06-05, no further updates yet).
• Judge panel: Not yet assigned or publicly available.
• Petition grounds: Not yet publicly available.
• Institution decision: Not yet issued.
• Final Written Decision (if issued): Not applicable, as the proceeding is pending institution.
• Settlement / termination: Not applicable.
• Appeal: Not applicable.
• Defensive value: This proceeding is in its very early stages. It indicates that Teladoc Health, Inc. is challenging the patent, but the merits of their petition, including which claims are challenged and on what grounds, are not yet public. Until an institution decision is made, the impact on a defendant facing assertion is minimal, other than signaling a potential future narrowing of the patent's scope.

Strategic summary

Currently, all claims of US11675791 remain UNTESTED in a final PTAB decision. The single proceeding, IPR2026-00390, was filed very recently (2026-06-05) and is still in the preliminary stage, awaiting an institution decision. This means no claims have been canceled or sustained by the PTAB yet.

Regarding the estoppel landscape, since no institution decision has been made, there is no estoppel for any party, including the petitioner Teladoc Health, Inc., or any potential privies. All prior-art grounds remain available for challenges against this patent, subject to the statutory limitations of 35 U.S.C. § 315.

There are no discernible pattern signals yet, as this is the first recorded AIA trial proceeding for this patent. It's too early to tell if the patent owner will aggressively pursue PTAB appeals or if there will be multiple IPRs from the same or different petitioners.

Recommended next steps

For a defendant currently being asserted against, the key milestone to watch for IPR2026-00390 is the institution decision. The PTAB has a statutory deadline for issuing an institution decision, which is typically within six months of the preliminary response filing or the waiver of that response. If the IPR is instituted, it will provide insights into which claims are being challenged and on what grounds, potentially impacting any ongoing or future litigation strategies.